Esperion Therapeutics, Inc. (ESPR)
Jul 13, 2026 - ESPR was delisted
3.180
-0.010 (-0.31%)
Inactive · Last trade price on Jul 10, 2026
Esperion Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Esperion Therapeutics stock had an average target of $3.19, with a low estimate of $3.16 and a high estimate of $3.28.
Price Target: $3.19 (+0.31%)
Analyst Consensus: Hold
Price Target
Chart* Price targets were last updated on May 4, 2026.
Analyst Ratings
The average analyst rating for Esperion Therapeutics stock from 6 stock analysts was "Hold". This means that analysts believed this stock was likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 2 | 3 | 0 |
| Buy | 3 | 3 | 3 | 3 | 3 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 6 |
| Sell | 1 | 1 | 1 | 1 | 1 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 7 | 8 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Hold Maintains n/a | Hold | Maintains | n/a | n/a | May 12, 2026 |
| Jefferies | Jefferies | Hold Downgrades $3.28 | Hold | Downgrades | $3.28 | +3.14% | May 4, 2026 |
| H.C. Wainwright | H.C. Wainwright | Hold Downgrades $3.16 | Hold | Downgrades | $3.16 | -0.63% | May 4, 2026 |
| Piper Sandler | Piper Sandler | Hold Downgrades $9 → $3.16 | Hold | Downgrades | $9 → $3.16 | -0.63% | May 1, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Hold Downgrades $3.16 | Hold | Downgrades | $3.16 | -0.63% | May 1, 2026 |
Financial Forecast
Revenue This Year
337.60M
from 403.14M
Decreased by -16.26%
Revenue Next Year
456.69M
from 337.60M
Increased by 35.28%
EPS This Year
-0.21
from -0.11
EPS Next Year
0.29
from -0.21
EPS and Forward PE are based on non-GAAP adjusted numbers.